Challenges remained in Thomson Reuters’ markets division in Q2, as the unit’s revenue was down 4 percent while its profits dropped 25 percent (though the company pointed out that excluding currency changes, the decline was more like 15 percent). That served as a drag on Thomson Reuters’ earnings generally this past quarter. The declines stemmed from residual weakness in the financial industry, which Thomson Reuters (NYSE: TRI) primarily caters to. Despite the negative numbers, in a statement, CEO Tom Glocer cited improving trends for the company overall in Q3 and said he expected a return to revenue growth in Q3. The Markets division, which includes media, sales & trading, investment & advisory and enterprise, is the largest part of the company.
Looking specifically at the media segment within the markets division, Q2 revenues fell 3 percent, which was attributed to weakness in the agency business. On the plus side, net sales in the quarter turned positive thanks to a rekindling of its news services relationship with CNN.
Still, as weak as the advertising recovery is, it helped boost revenues for the company’s consumer business by double-digits. The additional ad revenues were at least partly driven by the introduction of several new mobile products, including NewsPro for the iPad during the quarter.
The liar CEO Thomas Henry Glocer ia always make excuse for his idiotness to run the company.
The share price of Thomson Reuters is over value ,should be below 20 USD per share.,
Thomson Reuters is one of the worst company,due to corporate malfeasance as well as poor corporate governance.
Thomson Reuters is the company that has zero integrity,credibility and dignity as well.
Thomas Henry Glocer and Devin Wenig are the senior executives whose making “Reuters journalistic prostitution” by abuse of power to control Reuters editorial whether to run or to kill the news ,
Tom Glocer and Devin Wenig are unquestionable have expertise and talent in maling wrongful inducement to cover or veil their misconduct as well as misbehavior.